Repligen Corporation

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Repligen Corporation
Ownership: Public
Status: Active
Headquarters country: United States
Ticker symbol: RGEN
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000730272

Board of directors

Follow this board

Anthony Hunt · Director
Since 2023
Glenn P. Muir · Director
Since 2023
Karen A. Dawes · Director
Since 2023
Konstantin Konstantinov · Director
Since 2023
Manner Carrie Eglinton · Director
Since 2023
Margaret Pax · Director
Since 2024
Martin D. Madaus · Director Overboarded
Since 2023
Nicolas Barthelemy · Director
Since 2023
Olivier Loeillot · Director · Chief Executive Officer
Since 2024
Rohin Mhatre · Director
Since 2023

Chief executives

Olivier Loeillot · Chief Executive Officer

Dates unknown

Board connections

4 of this board's directors also sit on 9 other boards.

Shared director Other board Same sector

908 Devices Inc.
via Anthony Hunt
Azenta Inc.
via Martin D. Madaus
BioLife Solutions Inc.
via Anthony Hunt
Cytek Biosciences Inc.
via Glenn P. Muir
Haemonetics Corporation
via Martin D. Madaus
Neuronetics Inc.
via Glenn P. Muir
OraSure Technologies Inc.
via Manner Carrie Eglinton
Quanterix Corporation
via Martin D. Madaus
Standard BioTools Inc.
via Martin D. Madaus

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $14,225,636; 23 sales by 5 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 24, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Option exercise	+8,404	$154.96	$1,302,284
Sep 24, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Open-market sale	−8,404	$190.00	$1,596,760
Sep 24, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Option exercise	+4,542	$155.38	$705,736
Sep 24, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Open-market sale	−4,542	$190.00	$862,980
Sep 21, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Option exercise	+5,426	$141.79	$769,353
Sep 21, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Open-market sale	−5,426	$180.00	$976,680
Sep 4, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Open-market sale	−3,035	$165.90	$503,507
Sep 3, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Shares withheld for tax	−2,842	$169.61	$482,032
Sep 1, 2026	Hughes Violetta Officer (CHIEF ACCOUNTING OFFICER)	Shares withheld for tax	−277	$170.02	$47,096
Aug 20, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Option exercise	+5,426	$141.79	$769,353
Aug 20, 2026	Olivier Loeillot Director, Officer (Chief Executive Officer)	Open-market sale	−5,426	$180.00	$976,680
Jul 16, 2026	Garland Jason K Officer (CFO)	Open-market sale	−530	$150.00	$79,500
Jun 25, 2026	Garland Jason K Officer (CFO)	Open-market sale	−733	$145.00	$106,285
May 14, 2026	Konstantin Konstantinov Director	Grant or award	+995	—	—
May 14, 2026	Martin D. Madaus Director	Grant or award	+995	—	—

Reviews (0)

No reviews yet. Be the first to write one.